LNP023B
Total Payments
$30,732
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $30,732 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $30,732 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPEN-LABEL, NON-RANDOMIZED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF LNP023 IN SUBJECTS WITH C3 GLOMERULOPATHY | Novartis Pharmaceuticals Corporation | $30,732 | 0 |
Top Doctors Receiving Payments for LNP023B
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Iowa City, IA | $30,732 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $30,732
- Total Doctors 0
- Transactions 1
About LNP023B
LNP023B is a drug associated with $30,732 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $30,732 was paid across 1 transactions to 0 doctors.
The most common payment nature for LNP023B is "Unspecified" ($30,732, 100.0% of total).
LNP023B is associated with 1 research study, including "AN OPEN-LABEL, NON-RANDOMIZED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF LNP023 IN SUBJECTS WITH C3 GLOMERULOPATHY" ($30,732).